China grants 1st patent to indigenously developed Covid vaccine

Gallery

MORE...

Sports

Harmanpreet Singh named FIH Player of the Year, PR Sreejesh gets best goalkeeper award

Indian men's hockey team captain Harmanpreet Singh has been named Player of the Year 2024

World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17

U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals

FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup

Hockey, cricket, wrestling, badminton, squash axed from 2026 CWG in Glasgow

FIFA : Over 100 female footballers urge FIFA to reconsider partnership with Saudi oil giant

MORE...

China grants 1st patent to indigenously developed Covid vaccine

Last Updated : 17 Aug 2020 02:12:51 PM IST

File Photo

China has granted the first invention patent to a coronavirus vaccine co-developed by biopharmaceutical firm CanSino Biologics Inc in the country, which experts said demonstrates the vaccine's originality and creativity.

According to a Global Times report, the vaccine is a recombinant adenovirus vaccine named Ad5-nCoV co-developed by CanSino with a team led by Chinese military infectious disease expert Chen Wei.

"The grant of the patent further confirmed the vaccine's efficacy and safety, and convincingly demonstrated the ownership of its intellectual property rights (IPR)," CanSino said in a statement on Sunday.

An officially granted patent would enhance the market's confidence in Chinese-developed Covid-19 vaccines, "especially that of the international market".

"The US has been making accusations since May that Chinese hackers were attempting to steal novel coronavirus data on treatments and vaccines without providing substantial evidence," said the report.

According to CanSino, they applied for a patent with the National Intellectual Property Administration on March 18, three days after they launched phase one clinical trials on the candidate and received approval on August 11.

The phase III trial on the vaccine "which will be conducted overseas is progressing smoothly," the company said in the statement.

CanSino has signed deals with Mexico to conduct late-stage clinical trials for Covid-19 vaccines.

Saudi Arabian health officials also announced on August 9 to cooperate with phase III clinical trials on the vaccine, recruiting around 5,000 participants.

CanSino has also reportedly been in talks with Russia, Brazil and Chile to launch a Phase III trial on Ad5-nCOV.

Meanwhile, Russia has begun production of the first batch of vaccines against Covid-19, its health ministry said in a statement over the weekend.

The world's first registered vaccine against the novel coronavirus was announced by President Vladimir Putin last week, during an online meeting with government officials.

The third stage of the research on the world's first registered vaccine against the novel coronavirus, called Sputnik V, may begin in 7-10 days.

According to the Tass news agency, several tens of thousands of people are expected to take part in this research of the vaccine created by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Russian Health Ministry.

The vaccine Sputnik V, which is named after the space satellite launched by Moscow in 1957, was created by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, alongside the Russian Direct Investment Fund.